Cheetham Janet K

Duncan Jacque L, Liang Wendi, Maguire Maureen G, Audo Isabelle, Ayala Allison R, Birch David G et al.

Birch David G, Duncan Jacque L, Samarakoon Lassana, Melia Michele, Audo Isabelle, Ayala Allison R et al.

This study found dark-adapted visual fields in USH2A patients worsen ~1 dB/year, comparable to full-field rod ERG changes. This highlights DAVF as a sensitive, clinically relevant measure of rod-mediated progression.

Parekh Bela, Peck-Dimit Nicholas, Duncan Jacque L, Samarakoon Lassana, Abalem Maria Fernanda, Andrews Chris A et al.

This study found the VALVVFQ-48 questionnaire may not be sensitive enough to track long-term functional vision changes in all USH2A patients, despite some decline in scores.

Duncan Jacque L, Maguire Maureen G, McDaniel Lee S, Doucet Nicole R, Audo Isabelle, Ayala Allison R et al.

This study tracked visual field loss in USH2A patients over 4 years, finding all measures declined, with peripheral vision and central sensitivity showing significant changes. These measures are useful for monitoring disease progression.

Duncan Jacque L, Liang Wendi, Maguire Maureen G, Audo Isabelle, Ayala Allison R, Birch David G et al.

Maguire Maureen G, Birch David G, Duncan Jacque L, Ayala Allison R, Ayton Lauren N, Cheetham Janet K et al.

This study identified sensitive measures for USH2A retinal degeneration trials, finding static perimetry's rate of change and microperimetry/FST's within-eye changes are key, informing future trial design.

Birch David G, Samarakoon Lassana, Melia Michele, Duncan Jacque L, Ayala Allison R, Audo Isabelle et al.

Dark-adapted visual fields revealed rod function in most USH2A patients, even without measurable rod ERGs, suggesting DAVF may be a sensitive tool for monitoring rod-mediated disease progression.

Duncan Jacque L, Liang Wendi, Maguire Maureen G, Audo Isabelle, Ayala Allison R, Birch David G et al.

This study found Usher syndrome type 2 patients had worse visual fields than USH2A-related ARRP. Visual field total hill of vision was a repeatable, reliable measure of disease severity, correlating with other functional and structural metrics.

Cohen John S, Gross Ronald L, Cheetham Janet K, VanDenburgh Amanda M, Bernstein Paula, Whitcup Scott M

This 2-year study found bimatoprost once daily significantly lowered IOP more than timolol in glaucoma patients, offering superior long-term pressure control despite higher hyperemia incidence.